BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, March 28, 2024
See today's BioWorld
Home
» SARcode's Work in Dry Eye Attracts $44M Series B Round
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
SARcode's Work in Dry Eye Attracts $44M Series B Round
July 18, 2011
By
Jennifer Boggs
No Comments
Late last year, SARcode Bioscience Inc.'s new CEO indicated in a BioWorld interview plans for a Series B round early in 2011 to take its dry eye drug candidate into pivotal testing. (See BioWorld Today, Dec. 29, 2010.)
BioWorld